INTECH Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

INTECH Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397K	Hold	108,308	–	–	﹤0.01%	1452
2026 Q1	$333K	Sell	108,308 -47,026	-30%	-$182K	﹤0.01%	1528
2025 Q4	$635K	Sell	155,334 -3,919	-2%	-$19.4K	0.01%	1373
2025 Q3	$777K	Sell	159,253 -34,124	-18%	-$179K	0.01%	1329
2025 Q2	$978K	Buy	193,377 +46,068	+31%	+$226K	0.01%	1206
2025 Q1	$779K	Buy	147,309 +53,900	+58%	+$393K	0.01%	1356
2024 Q4	$631K	Buy	93,409 +40,456	+76%	+$272K	0.01%	1426
2024 Q3	$349K	Buy	+52,953	New	+$380K	﹤0.01%	1427

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

INTECH Investment Management's RXRX Position: Q2 2026 in Review

INTECH Investment Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 108,308 shares worth $397K. The position accounts for ﹤0.01% of the portfolio, ranked #1452.

INTECH Investment Management first reported a position in RXRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $978K in Q2 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

INTECH Investment Management held 108,308 shares of Recursion Pharmaceuticals worth $397K as of Q2 2026.
INTECH Investment Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1452 holding.
INTECH Investment Management first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Recursion Pharmaceuticals position peaked at $978K in Q2 2025.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.